Cabernet Pharmaceuticals and Eli Lilly and Company Form Pharmacogenetics Alliance to Help Deliver Tailored Therapeutics to Patients

DURHAM, N.C. & INDIANAPOLIS--(BUSINESS WIRE)--Cabernet Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE:LLY) today announced an alliance to further integrate pharmacogenetics into Lilly’s drug-development efforts.
MORE ON THIS TOPIC